Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 3, 2011, Pages 309-313

  Yafi, Faysal A ^a   Duclos, Marie ^a   Correa, José A ^b   Tanguay, Simon ^a   Aprikian, Armen G ^a   Cury, Fabio ^a   Souhami, Luis ^a   Rajan, Raghu ^a   Kassouf, Wassim ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Bladder; Bladder neoplasm; Cystectomy; Pelvic lymph node dissection; Staging; Unresectable

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

AGED; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA IN SITU; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CYSTECTOMY; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; HYDRONEPHROSIS; LYMPH NODE DISSECTION; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MONOTHERAPY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUPERFICIAL CANCER; SURVIVAL TIME; UNRESECTABLE BLADDER CANCER;

AGED; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79955724277     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.04.017     Document Type: Article

References (10)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
2. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogenous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
3. Herr H.W., Donat S.M. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 2001, 165:62-64.
4. Donat S.M., Herr H.W., Bajorin D.F., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 1996, 156:368-371.
5. Herr H.W., Donat S.M., Bajorin D.F. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001, 165:811-814.
6. Guzzo T.J., Rogers C.G., Deng C.Y., et al. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU Int 2008, 102:1539-1543.
7. Vieweg J., Gschwend J.E., Herr H.W., et al. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999, 161:449-454.
8. Kassouf W., Agarwal P.K., Herr H.W., et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008, 26:121-126.
9. Stein J.P. Lymphadenectomy in bladder cancer: How high is "high enough"?. Urol Oncol 2006, 24:349-355.
10. Stein J.P., Cai J., Groshen S., et al. Risk factors for patients with pelvic lymph node metastasis following radical cystectomy with en bloc pelvic lymphadenectomy: Concept of lymph node density. J Urol 2003, 170:35-41.